Evidence map›Paper›PMID 37777762›Full record

ArticleBMC research notes2023

Piloting a forced-choice task to elicit treatment preferences in geographic atrophy.

Jamie Enoch, Arevik Ghulakhszian, Mandeep Sekhon, David P Crabb, Deanna J Taylor, Christiana Dinah

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC research notes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Jamie EnochDepartment of Optometry and Visual Sciences, City, University of London, London, UK.
Arevik GhulakhszianOphthalmology Department, London North West University Healthcare NHS Trust, Central Middlesex Hospital, London, UK.
Mandeep SekhonCentre for Applied Health and Social Care Research, Kingston and St George's, University of London, London, UK.
David P CrabbDepartment of Optometry and Visual Sciences, City, University of London, London, UK.
Deanna J TaylorDepartment of Optometry and Visual Sciences, City, University of London, London, UK.
Christiana DinahOphthalmology Department, London North West University Healthcare NHS Trust, Central Middlesex Hospital, London, UK. christiana.dinah@nhs.net.
City, University of London · GBCentral Middlesex Hospital · GBLondon North West Healthcare NHS Trust · GBSt George's, University of London · GB

Funding

Apellis Pharmaceuticals AMR-000001City, University of London Higher Education Innovation Fund
6 · The paper itself

Abstract

objectiveGeographic Atrophy (GA) is the advanced form of the non-neovascular ('dry') type of age-related macular degeneration (AMD) and responsible for one-quarter of legal blindness in the UK. New therapies delivered by intravitreal injection are in late-stage development, and two such therapies (pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay)) have now been approved for clinical use by the US Food and Drug Administration. These therapies slow down, but do not stop or reverse, progression of GA and they may also increase the risk of developing the neovascular ('wet') type of AMD. Within a larger study exploring the acceptability of these new treatments to people living with GA, we developed a forced-choice exercise to evaluate how participants weigh up benefits and drawbacks of different treatment regimens. This research note reports quantitative and qualitative findings from this exercise.

resultsTwenty-eight participants took part in this exercise. The exercise demonstrated that participants were generally, although not unanimously, in favour of less frequent treatment for GA that was slightly less efficacious in terms of preserving visual function but presented a lower risk of developing wet AMD. Even among a small sample, the exercise demonstrated the highly personal and idiosyncratic decision-making processes influencing participants' choices of preferred hypothetical GA treatment.

Indexed as

Geographic AtrophyMacular DegenerationHumansAcceptabilityComplement inhibitorsGeographic atrophyIntravitreal injectionsQualitative research

Identifiers

PMID37777762
PMCPMC10543887
OpenAlexW4387216070

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.